|Bid||14.25 x 4000|
|Ask||14.45 x 800|
|Day's Range||13.49 - 14.45|
|52 Week Range||6.00 - 24.26|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.00|
Is (CLGN) Outperforming Other Medical Stocks This Year?
CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced the appointment of Hugh Evans to its Board of Directors, increasing the board to six independent members.
CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced financial results for the full year ended December 31, 2020 and provided an update on the Company's business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures. See "Use of Non-GAAP Measures" below.